The role of ulinastatin in the treatment of acute-on-chronic liver failure: a retrospective cohort study

Abstract

Abstract: Objective To investigate the efficacy of ulinastatin in the treatment of acute-on-chronic liver failure (ACLF). Methods Ninty patients with ACLF admitted to our hospital from January 2015 to December 2016 were enrolled in our single-center retrospective cohort study. The patients were divided into control group (treated with routine therapy) and experimental group (treated with ulinastatin added to routine therapy). There was no significant difference in demographics between the 2 groups. Results The therapeutic efficacy in the experimental group was significantly better than the control group (70% vs 45%, P=0.025), and the mortality rate was lower than the control group (27.6% vs 51.9%, P=0.0487). The incidence of spontaneous bacterial peritonitis was significantly lower in the experimental group (26.67% vs 50.00%, P=0.0346), while the rates of other complications had no statistical difference (P>0.05). Conclusion Ulinastatin added to routine therapy can improve the prognosis and reduce the incidence of spontaneous bacterial peritonitis in ACLF patients. Further prospective studies are warranted to verify the efficacy of ulinastatin in the treatment of liver failure.

Key words: Ulinastatin, Acute-on-chronic liver failure, Efficacy, Spontaneous bacterial peritonitis

ZHANG Xiu-cui, LI Ming-long, HANG Xiao-feng, WEI Bo. The role of ulinastatin in the treatment of acute-on-chronic liver failure: a retrospective cohort study[J]. Chinese Hepatolgy, 2021, 26(7): 776-778.

References

[1] Mehta G, Mookerjee RP, Sharma V, et al. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. Liver Int, 2015,35:724-734.
[2] Kubes P, Mehal WZ,et al. Sterile inflammation in the liver. Gastroenterology, 2012,143:1158-1172.
[3] Wang LZ, Luo MY, Zhang JS, et al. Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment: a meta-analysis. Int J Clin Pharmacol Ther, 2016,54:890-898.
[4] Wang FY, Fang B, Qiang XH, et al. The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin alpha1 for Sepsis: A Systematic Review and Meta-Analysis. Biomed Res Int, 2016,2016:9508493.
[5] Li X, Li J, Ou YJ, et al. Hepatoprotective effect of ulinastatin in a rat model of major hepatectomy after obstructive jaundice. Dig Dis Sci, 2015,60:1680-1689.
[6] Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int, 2014,8:453-471.
[7] Liver Failure And Artificial Liver Group, Chinese Society Of Infectious Disease,CMA; Severe Liver Disease And Artificial Liver Group, Chinese Society Of Hepatology,CMA.Diagnostic and treatment guidelines for liver failure (2012 version). Zhonghua Gan Zang Bing Za Zhi, 2013,21:177-183.
[8] Lin SD, Endo R, Kuroda H, et al. Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma. J Gastroenterol Hepatol, 2004,19:327-332.
[9] Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014,60:250-256.
[10] Dhiman RK, Makharia GK, Jain S, et al. Ascites and spontaneous bacterial peritonitis in fulminant hepatic failure. Am J Gastroenterol, 2000,95:233-238.
[11] Khot AA, Somani P, Rathi P, et al. Prognostic factors in acute-on-chronic liver failure: a prospective study from western India. Indian J Gastroenterol, 2014,33:119-124.
[12] Li Y, Zhao L, Fu H, et al. Ulinastatin suppresses lipopolysaccharide induced neuro-inflammation through the downregulation of nuclear factor-kappaB in SD rat hippocampal astrocyte. Biochem Biophys Res Commun, 2015,458:763-770.
[13] Wu YJ, Ling Q, Zhou XH, et al. Urinary trypsin inhibitor attenuates hepatic ischemia-reperfusion injury by reducing nuclear factor-kappa B activation. Hepatobiliary Pancreat Dis Int, 2009,8:53-58.
[14] Chen X, Wang Y, Luo H, et al. Ulinastatin reduces urinary sepsisrelated inflammation by upregulating IL10 and downregulating TNFalpha levels. Mol Med Rep, 2013,8:29-34.
[15] Huang N, Wang F, Wang Y, et al. Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res, 2013,182:296-302.
[16] Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014,60:250-256.